Nyrada reports $8.4M cash in annual results
- Nyrada posted $8.4 million after closing an $8.3 million capital raise.
- The biotech's stock remained stable at $0.72 as cash reserves expanded from $2.9 million year-on-year.
- Capital reserves fully fund ongoing Phase IIa clinical and preclinical drug development programmes.
Biotech firm Nyrada (ASX:NYR) released its 2026 financial year audited accounts, showing $8.4 million in cash reserves as of June 30.
The figure contrasts with $2.9 million recorded at the end of FY25 following an $8.3 million capital placement in August 2025.
The clinical-stage biotech did not include an executive statement in the summary announcement.
Secondary metrics show an expected $1.7 million R&D tax rebate due by Dec. 31 following a previous $2.5 million FY25 tax receipt.
The company stated that current cash reserves fully fund both clinical and preclinical programmes through current trial targets.
Following the announcement, the Nyrada share price was unchanged at $0.72.
The business is progressing its Phase IIa PROTECT-MI trial, evaluating Xolatryp in heart-attack patients.
Preparation also commenced for a US FDA Investigational New Drug application scheduled for submission before the end of 2026.
